A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

• A. González ^[18] ; A. Lluch ^[6] ; E. Aba ^[7] ; J. Albanell ^[19] ; A. Antón ^[8] ; I. Álvarez ^[9] ; F. Ayala ^[20] ; A. Barnadas ^[10] ; L. Calvo ^[11] ; E. Ciruelos ^[12] ; J. Cortés ^[13] ; J. de la Haba ^[14] ; J. M. López-Vega ^[15] ; E. Martínez ^[21] ; M. Muñoz ^[1] ; I. Peláez ^[2] ; A. Redondo ^[3] ; Á. Rodríguez ^[4] ; C. A. Rodríguez ^[16] ; A. Ruíz ^[5] ; A. Llombart ^[17]
  1. [1] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  2. [2] Hospital de Cabueñes

     Hospital de Cabueñes

     Gijón, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  6. [6] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  7. [7] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  8. [8] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  9. [9] Hospital Universitario de Donostia

     Hospital Universitario de Donostia

     San Sebastián, España

     
  10. [10] Hospital de la Santa Creu i Sant Pau

      Hospital de la Santa Creu i Sant Pau

      Barcelona, España

      
  11. [11] Complexo Hospitalario Universitario da Coruña

      Complexo Hospitalario Universitario da Coruña

      A Coruña, España

      
  12. [12] Hospital Universitario 12 de Octubre

      Hospital Universitario 12 de Octubre

      Madrid, España

      
  13. [13] Hospital Ramón y Cajal

      Hospital Ramón y Cajal

      Madrid, España

      
  14. [14] Hospital Universitario Reina Sofia

      Hospital Universitario Reina Sofia

      Cordoba, España

      
  15. [15] Hospital Universitario Marqués de Valdecilla

      Hospital Universitario Marqués de Valdecilla

      Santander, España

      
  16. [16] Hospital Universitario de Salamanca-IBSAL, España
  17. [17] Hospital Universitario Arnau Vilanova, España
  18. [18] MD Anderson Cancer Center, España
  19. [19] Hospital Parc de Salut Mar, España
  20. [20] Hospital Universitario Morales Meseguer, España
  21. [21] Fundación Hospital Provincial de Castellón, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 5 (May 2017), 2017, págs. 616-624
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Purpose To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology.

    Methods A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement.

    Results Among the 88 oncologists that were invited to participate, 81 answered the first round (92%), 70 answered the second round (80%), and 67 answered the third round (76%) of the survey. There was strong agreement regarding the fact that identifying patients with aggressive disease needs to be adequately addressed to help practitioners to decide the best treatment options for patients with HER2-negative mBC. The factors that were considered to be strongly relevant to classifying patients with aggressive HER2-negative mBC were a high tumor burden, a disease-free interval of less than 12–24 months after surgery, the presence of progressive disease during adjuvant or neoadjuvant chemotherapy and having a triple-negative phenotype. The main therapeutic goals were controlling symptoms, improving quality of life and increasing the time to progression and overall survival.

    Conclusions High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.